Antithrombotika und Antihämorrhagika

Zusammenfassung

Antithrombotika (Antikoagulantien, Thrombozytenaggregationshemmer) werden bei venösen und arteriellen thromboembolischen Gefäßkrankheiten mit unterschiedlichen therapeutischen Zielen eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist weiterhin die Standardtherapie für akute tiefe Venenthrombosen und Lungenembolien. Daneben werden Vitamin-KAntagonisten zur Prophylaxe kardiogener Hirnembolien bei Vorhofflimmern sowie bei Herzklappenerkrankungen und nach Klappenersatz angewendet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis (2013): Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34: 1708–13, 1713a–1713bGoogle Scholar
  2. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013a): Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369: 799–808Google Scholar
  3. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators P-E (2013b): Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368: 699–708Google Scholar
  4. Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P, Schünemann H (2011): Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 6: CD006650Google Scholar
  5. Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342Google Scholar
  6. Alikhan R, Cohen AT (2009): Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD003747Google Scholar
  7. Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86Google Scholar
  8. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009): Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849–1860Google Scholar
  9. AWMF Leitlinien-Register Nr. 065/002, Klasse S2k: Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Stand: 10.10.2015. Unter: http://www.awmf.org/awmf-online-das-portal-der-wissenschaftlichen-medizin/awmf-aktuell.html; Zugriff 1.6.2017
  10. Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, Feit F (2014): Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 349: g6419Google Scholar
  11. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators (2010): Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363: 1909–1917Google Scholar
  12. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717Google Scholar
  13. Björck F, Sandén P, Renlund H, Svensson PJ, Själander A (2016): Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res 136: 216–220Google Scholar
  14. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014): Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63: 872–877Google Scholar
  15. Bundesinstitut für Arzneimittel und Medizinprodukte (2017): Unter http://www.bfarm.de/DE/Service/Presse/Themendossiers/NOAK/_node.html; Zugriff 1.6.2017
  16. Bundesministerium für Gesundheit (2012a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Korrektur der Arzneimittel-Richtlinie (AMR) in Anlage 10: Clopidogrel. BAnz. Nr. 161 (S. 3 814) vom 23.10.2008Google Scholar
  17. Bundesministerium für Gesundheit (2012b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Ticagrelor vom 15. Dezember 2011, BAnz Nr. 11 vom 19.01.2012Google Scholar
  18. Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht der Verordnungseinschränkungen und –ausschlüsse Dipyridamol in Kombination mit Acetylsalicylsäure vom 16. Mai 2013, veröffentlicht am Dienstag, 25. Februar 2014 BAnz AT 25.02.2014 B2Google Scholar
  19. CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339Google Scholar
  20. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244Google Scholar
  21. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009): Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–317Google Scholar
  22. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators (2009): Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361: 1139–1151Google Scholar
  23. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators (2011): Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806–817Google Scholar
  24. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014): Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64: 1128–1139Google Scholar
  25. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI (2013): Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110: 1087–1107Google Scholar
  26. Dentali F, Douketis JD, Lim W, Crowther M (2007): Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 167: 117–124Google Scholar
  27. De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080Google Scholar
  28. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337Google Scholar
  29. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators (2013): Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369: 1206–1214Google Scholar
  30. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655Google Scholar
  31. Eikelboom JW, Quinlan DJ, O’Donnell M (2009): Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 120: 2006–2011Google Scholar
  32. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S (2005): Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112: 3855–3867Google Scholar
  33. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008): Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358: 2765–2775Google Scholar
  34. Erkens PM, Prins MH (2010): Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 9: CD001100Google Scholar
  35. European Medicines Agency (2011): Updates on safety of PRADAXA; Pressemitteilung vom 18. Nov. 2011.Internet : www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf
  36. Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM. Kreuth III (2014): European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 20: 322–325Google Scholar
  37. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators (2013): Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093–2104Google Scholar
  38. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E (2012): Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 344: e3675Google Scholar
  39. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999): Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800–809Google Scholar
  40. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators (2011): Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992Google Scholar
  41. Greinacher A, Warkentin TE (2008): Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. Expert Rev Hematol 1: 75–85Google Scholar
  42. Greinacher A (2015): Heparin-Induced Thrombocytopenia. N Engl J Med 373: 252–261Google Scholar
  43. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235Google Scholar
  44. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators (2017): Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376: 32–40Google Scholar
  45. Hohnloser SH, Basic E, Nabauer M (2017). Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol, Epub ahead of print 2017 Mar 14, doi:  10.1007/s00392-017-1098-x
  46. Hoots WK, Nugent DJ (2006): Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440Google Scholar
  47. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002): Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 347: 969–974Google Scholar
  48. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2006): Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen. Abschlussbericht A04/01A. Stand 30.06.2006. Internet: https://www.iqwig.de/download/A04-01A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf
  49. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011a): Dipyridamol + ASS zur Sekundärprävention nach Schlaganfall oder TIA. Abschlussbericht A09-01. Stand 14.02.2011. Internet: https://www.iqwig.de/download/A09-01_Abschlussbericht_Dipyridamol_ASS_nach_Schlaganfall_oder_TIA.pdf
  50. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011b): Prasugrel bei akutem Koronarsyndrom. Abschlussbericht A09-02. Stand 11.07.2011. Internet: https://www.iqwig.de/download/A09-02_Abschlussbericht_Prasugrel_bei_akutem_Koronarsyndrom.pdf
  51. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members (2014): 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130: 2071–2104Google Scholar
  52. Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators (2015): Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 13: 360–369Google Scholar
  53. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians (2012): Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 2 Suppl): e419S–94SGoogle Scholar
  54. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016): ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37: 2893–2962Google Scholar
  55. Koch A, Ziegler S, Breitschwerdt H, Victor N (2001): Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 102: 295–309Google Scholar
  56. Kodumuri V, Adigopula S, Singh P, Swaminathan P, Arora R, Khosla S (2011): Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis. Am J Ther 18: 180–189Google Scholar
  57. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY (2016): Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353: i3189Google Scholar
  58. Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607Google Scholar
  59. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith SC Jr; Focused Update Writing Group (2016): 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 133: im DruckGoogle Scholar
  60. Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, Rusen L, Ghinea M, Uscatescu V, Rescia V, Hong W (2014): Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 11: 1119–1127Google Scholar
  61. Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–2715Google Scholar
  62. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators (2014): Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 2155–2166Google Scholar
  63. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533Google Scholar
  64. Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930Google Scholar
  65. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E (2007): Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28: 2077–2086Google Scholar
  66. National Institute for Care Exellence (2014): Atrial fibrillation: the management of atrial fibrillation. Issued: June 2014 last modified: August 2014. NICE clinical guideline 180. Internet: guidance.nice.org.uk/cg180Google Scholar
  67. Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH (2012): Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 156: 710–719Google Scholar
  68. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB (2017): Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356: j510Google Scholar
  69. Othieno R, Abu Affan M, Okpo E (2007): Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 3: CD003076Google Scholar
  70. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010): Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362: 1374–1382Google Scholar
  71. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (2011): Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891Google Scholar
  72. Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, Carrier M (2013): Outpatient treatment of symptomatic pulmonary embolism: a systematic review and metaanalysis. Thromb Res 132: 515–519Google Scholar
  73. Qiao J, Zhang X, Zhang J, Li P, Xu B, Wang S, Jiang H, Shen Y, Wang K (2016): Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: A meta-analysis. Cardiology 133: 163–172Google Scholar
  74. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators (2012): Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367: 1297–1309Google Scholar
  75. Romualdi E, Donadini MP, Ageno W (2011): Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 9: 841–844Google Scholar
  76. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014): Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129: 764–772Google Scholar
  77. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS (2009): Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342–2352Google Scholar
  78. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators (2013): Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368: 709-718Google Scholar
  79. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009): Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375Google Scholar
  80. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A (2015): Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 113: 1370–1377Google Scholar
  81. Stangier J, Rathgen K, Stahle H, Mazur D (2010): Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single- centre study. Clin Pharmacokinet 49: 259–268Google Scholar
  82. The ACTIVE Writing Group of the ACTIVE Investigators (2006): Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-1912Google Scholar
  83. The ACTIVE Investigators (2009): Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078Google Scholar
  84. The EINSTEIN Investigators (2010): Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499–2510Google Scholar
  85. The EINSTEIN-PE Investigators (2012): Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287–1297Google Scholar
  86. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502Google Scholar
  87. The Hokusai-VTE Investigators (2013): Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369: 1406–1415Google Scholar
  88. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007): Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227Google Scholar
  89. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M (2009): Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057Google Scholar
  90. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators (2017): Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 376: 1211–1222Google Scholar
  91. White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20Google Scholar
  92. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014): 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541–2619Google Scholar
  93. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007): Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015Google Scholar
  94. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA (2016): Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 5. pii: e003074Google Scholar
  95. Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Institut für Experimentelle und Klinische Pharmakologie und ToxikologieAlbert-Ludwig-UniversitätFreiburgDeutschland
  2. 2.Institut für Klinische Pharmakologie Klinikum Bremen-MitteGesundheit Nord gGmbHBremenDeutschland

Personalised recommendations